av/eliem-therapeutics--big.svg

NASDAQ:ELYM

Eliem Therapeutics

  • Stock

5.11

−0.97%

−0.05

USD last updated 11/08 02:03:55

Last Close

5.16

02/10 20:00

Market Cap

478.85M

Beta: -

Volume Today

802.69K

Avg: 17.85K

PE Ratio

−1.98

PFCF: −2.60

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -3-2-12020-03-312021-03-312022-05-162023-05-112024-03-042024-08-08

    Revenue (Estimate*)

    0.000.000.010.010.012020-03-312021-03-312022-05-162023-05-112024-03-042024-08-08

    *Estimate based on analyst consensus